$345.2 M

CBMG Mkt cap, 22-Jun-2018

$51 K

Cellular Biomedicine Group Revenue Q1, 2018
Cellular Biomedicine Group Gross profit (Q1, 2018)28.7 K
Cellular Biomedicine Group Gross profit margin (Q1, 2018), %56.2%
Cellular Biomedicine Group Net income (Q1, 2018)-8.5 M
Cellular Biomedicine Group EBIT (Q1, 2018)-8.5 M
Cellular Biomedicine Group Cash, 31-Mar-201845.6 M

Cellular Biomedicine Group Financials

Cellular Biomedicine Group Income Statement

Annual

USDFY, 2016FY, 2017

Revenue

627.9 k336.8 k

Cost of goods sold

860.4 k162.2 k

Gross profit

(232.5 k)174.6 k

Gross profit Margin, %

(37%)52%

Sales and marketing expense

360.8 k

R&D expense

11.5 m14.6 m

General and administrative expense

11.7 m12.8 m

Operating expense total

23.1 m27.9 m

EBIT

(28.4 m)(27.6 m)

EBIT margin, %

(4525%)(8187%)

Interest income

78.9 k133.6 k

Net Income

(28.2 m)(25.5 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

603.4 k657 k624.9 k488.5 k71.6 k10 k98.4 k51 k

Cost of goods sold

52 k459 k398.2 k443.4 k503.2 k323.6 k9.1 k37.4 k22.3 k

Gross profit

144.4 k258.7 k181.5 k(14.7 k)(252 k)884 61 k28.7 k

Gross profit Margin, %

24%39%29%(3%)(352%)9%62%56%

Sales and marketing expense

74.6 k

R&D expense

642.8 k737.8 k734.5 k1.3 m2.2 m2.4 m3 m2.9 m3 m5.3 m

General and administrative expense

1.7 m2 m3.5 m3.8 m3.5 m2.8 m3.1 m2.8 m3.2 m3.2 m

Operating expense total

2.4 m2.8 m4.2 m5.1 m5.7 m5.2 m6 m5.7 m6.2 m8.6 m

EBIT

(2.3 m)(2.8 m)(4.3 m)(5 m)(5.7 m)(5.4 m)(6.3 m)(10.4 m)(6.3 m)(8.5 m)

EBIT margin, %

(712%)(760%)(907%)(1099%)(8851%)(104105%)(6387%)(16696%)

Interest income

341 698 15.1 k5.9 k8.4 k17.1 k18.3 k22.3 k49.2 k5.4 k

Income tax expense

(800 )(52.2 k)(2.4 k)

Net Income

(6.7 m)(2.8 m)(4.3 m)(5 m)(5.1 m)(4.2 m)(7.2 m)(10.7 m)(6.2 m)(8.5 m)

Cellular Biomedicine Group Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

39.3 m21.6 m

Accounts Receivable

412.7 k

Inventories

Current Assets

40.7 m24.5 m

PP&E

4.1 m13 m

Goodwill

7.7 m7.7 m

Total Assets

68.6 m61.2 m

Accounts Payable

216.2 k225.3 k

Current Liabilities

2.4 m3.7 m

Total Liabilities

2.7 m3.9 m

Additional Paid-in Capital

152.5 m172.7 m

Retained Earnings

(85.5 m)(111 m)

Total Equity

65.9 m57.3 m

Financial Leverage

1 x1.1 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

13.6 m9.8 m31.1 m23.7 m20.1 m15.7 m47.5 m44.1 m33.4 m45.6 m

Accounts Receivable

24 k175.1 k340 k445.2 k410.8 k582.7 k245.1 k264.8 k813.1 k

Inventories

156.5 k347.8 k277.9 k400.1 k422.1 k486.3 k313.8 k253.2 k

Current Assets

14.2 m11.1 m32.6 m25.5 m21.7 m17.7 m49.2 m45.3 m35.3 m48.7 m

PP&E

819.9 k1.3 m1.4 m1.3 m1.7 m2.7 m3.2 m3.1 m4.4 m14.6 m

Goodwill

7.7 m7.7 m7.7 m7.7 m7.7 m7.7 m7.7 m7.7 m7.7 m

Total Assets

26.2 m41.6 m57.9 m67.1 m61.9 m71.3 m87.5 m72.7 m63.6 m86.7 m

Accounts Payable

109.1 k224.4 k160.2 k106.6 k146.4 k208.9 k136.4 k220.2 k782.5 k331.8 k

Current Liabilities

2.5 m4.9 m5 m5.2 m4.7 m3.2 m2.2 m1.9 m2 m5.2 m

Total Liabilities

5.4 m

Additional Paid-in Capital

49.8 m66.2 m95.8 m99.1 m101.3 m109.9 m148.8 m150.9 m154 m205.1 m

Retained Earnings

(29.5 m)(32.4 m)(42.2 m)(47.2 m)(52.3 m)(61.5 m)(68.7 m)(79.4 m)(91.7 m)(119.5 m)

Total Equity

23.7 m36.3 m52.7 m61.6 m56.9 m64.7 m85 m70.8 m61.2 m81.3 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1 x1 x1 x1.1 x

Cellular Biomedicine Group Cash Flow

Annual

USDFY, 2016FY, 2017

Net Income

(28.2 m)(25.5 m)

Depreciation and Amortization

2.6 m3 m

Accounts Receivable

537.2 k(160.6 k)

Inventories

514.7 k

Accounts Payable

(28.2 k)(814 )

Cash From Operating Activities

(15.9 m)(18.6 m)

Purchases of PP&E

(2.7 m)(10.2 m)

Cash From Investing Activities

(2.7 m)(10.2 m)

Cash From Financing Activities

43.3 m10.8 m

Income Taxes Paid

6.7 k2.5 k

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(6.7 m)(2.8 m)(4.3 m)(5 m)(5.1 m)(4.2 m)(7.2 m)(10.7 m)(6.2 m)(8.5 m)

Depreciation and Amortization

1.2 m

Accounts Receivable

24 k175.1 k340 k445.2 k410.8 k582.7 k245.1 k264.8 k813.1 k81.6 k

Inventories

156.5 k347.8 k277.9 k400.1 k422.1 k486.3 k313.8 k253.2 k

Accounts Payable

109.1 k224.4 k160.2 k106.6 k146.4 k208.9 k136.4 k220.2 k782.5 k26.6 k

Cash From Operating Activities

(5.6 m)

Purchases of PP&E

(1.1 m)

Cash From Investing Activities

(1.1 m)

Cash From Financing Activities

30.6 m

Cellular Biomedicine Group Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information